Efficacy and safety of intensive treatment versus standard treatment of compound danshen dripping pills in refractory angina patients unsuitable for revascularization: a multicenter, randomized, double-blind, parallel controlled clinical trial
Phase of Trial: Phase IV
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs T 89 (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- 14 Oct 2018 Planned number of patients changed from 168 to 10.
- 14 Oct 2018 Planned End Date changed from 30 Jun 2019 to 31 Dec 2020.
- 06 Dec 2017 New trial record